Janux Therapeutics JANX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.73M— | $0-100% | $10M— | $0— | $0— | ||
| $26.81M-15.0% | $31.55M-8.9% | $34.63M-0.1% | $34.66M+38.4% | $25.06M+20.4% | ||
| $11.13M+2.6% | $10.85M+2.2% | $10.62M+1.6% | $10.45M+6.2% | $9.84M+19.8% | ||
| $37.95M-10.5% | $42.4M-6.3% | $45.25M+0.3% | $45.12M+29.3% | $34.9M+20.2% | ||
| -$34.21M+19.3% | -$42.4M-20.3% | -$35.25M+21.9% | -$45.12M-29.3% | -$34.9M-20.2% | ||
| -916.5%— | —— | -352.5%— | —— | —— | ||
| $9.85M-5.8% | $10.46M-4.4% | $10.94M-2.9% | $11.26M-1.1% | $11.39M+29.3% | ||
| $9.85M-5.8% | $10.46M-4.4% | $10.94M-2.9% | $11.26M-1.1% | $11.39M+29.3% | ||
| -$24.36M+23.7% | -$31.95M-31.4% | -$24.31M+28.2% | -$33.86M-44.0% | -$23.51M-16.3% | ||
| -652.6%— | —— | -243.1%— | —— | —— | ||
| -$0.39+23.5% | -$0.51-30.8% | -$0.39+29.1% | -$0.55-44.7% | -$0.38-8.6% | ||
| -$0.39+23.5% | -$0.51-30.8% | -$0.39+29.1% | -$0.55-44.7% | -$0.38-8.6% | ||
| 62.7M+1.1% | 62M-0.1% | 62M+0.2% | 61.9M+0.2% | 61.8M+15.0% | ||
| 62.7M+1.1% | 62M-0.1% | 62M+0.2% | 61.9M+0.2% | 61.8M+15.0% | ||
| $9.85M-5.8% | $10.46M-4.4% | $10.94M-2.9% | $11.26M-1.1% | $11.39M+29.3% | ||
| -$34.21M+19.3% | -$42.4M-20.3% | -$35.25M+21.9% | -$45.12M-29.3% | -$34.9M-20.2% | ||
| -$33.74M+19.5% | -$41.93M-20.7% | -$34.75M+22.0% | -$44.58M-29.7% | -$34.38M-20.6% | ||
| -$33.74M+19.5% | -$41.93M-20.7% | -$34.75M+22.0% | -$44.58M-29.7% | -$34.38M-20.6% | ||
| -903.9%— | —— | -347.5%— | —— | —— | ||
| -$34.21M+19.3% | -$42.4M-20.3% | -$35.25M+21.9% | -$45.12M-29.3% | -$34.9M-20.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Janux Therapeutics's revenue?
- Janux Therapeutics (JANX) generated $13.7M in revenue over the trailing twelve months, up 47.1% year over year.
- Is Janux Therapeutics profitable?
- Janux Therapeutics is not currently profitable: it reported a net loss of $114.5M over the trailing twelve months, a -833.6% net margin.
- What is Janux Therapeutics's earnings per share?
- Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.84.
- Where does Janux Therapeutics's income statement data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
